Survival outcomes in patients receiving immune checkpoint inhibitor (ICI) for metastatic small cell urothelial cancer (SCUC).

Omar Alhalabi,Nathaniel R. Wilson,Neema Navai,Matthew T. Campbell,Amishi Yogesh Shah,Jianjun Gao,Paul G. Corn,Ana Aparicio,Bogdan Czerniak,Charles C. Guo,Christopher J. Logothetis,Nizar M. Tannir,Seungtaek Choi,Arlene O. Siefker-Radtke

Survival outcomes in patients receiving immune checkpoint inhibitor (ICI) for metastatic small cell urothelial cancer (SCUC).

2021

Omar Alhalabi
Nathaniel R. Wilson
Neema Navai
Matthew T. Campbell
Amishi Yogesh Shah
Jianjun Gao
Paul G. Corn
Ana Aparicio
Bogdan Czerniak
Charles C. Guo
Christopher J. Logothetis
Nizar M. Tannir
Seungtaek Choi
Arlene O. Siefker-Radtke

4543Background: The prognosis in patients with metastatic SCUC (mSCUC) remains poor with median survival around 1 year with systemic chemotherapy. We aimed to investigate the impact of ICI on survi...

Keywords:

Internal medicine
Cell
systemic chemotherapy
urothelial cancer
Medicine
Oncology
in patient
median survival
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations